Antiverse Raises $9.3 Million, Enters Research Agreement with Cystic Fibrosis Foundation

Rare Daily Staff

Antiverse, a biotech using artificial intelligence to design antibodies for traditionally “undruggable” targets, has raised $9.3 million in Series A funding and signed a new research agreement with the Cystic Fibrosis Foundation.

Soulmates Ventures led the financing round, with participation from Innovation Investment Capital, DOMiNO Ventures, and existing investors DBW, Kadmos Capital, and i&i Biotech Fund. The new round brings the company’s total funding to more than $20 million since its founding.

Antiverse said it will use the funds to advance its internal antibody pipeline toward in vivo efficacy studies, expand partnerships with pharmaceutical companies, and scale its proprietary AI antibody design platform.

As part of the new collaboration, Antiverse will work with the Cystic Fibrosis Foundation to design antibodies that bind to the extracellular region of the cystic fibrosis transmembrane conductance regulator (CFTR) protein — a target long considered difficult to drug with traditional antibody discovery methods.

Antiverse will design, build, and validate therapeutic-strength antibodies in-house before transferring candidates to the Foundation’s labs for testing in CFTR-expressing cell models. The work aims to accelerate early discovery of research tools and potential new treatments for cystic fibrosis.

“Many biologically important targets have remained difficult to drug using conventional antibody discovery methods,” said Antiverse co-founder and CEO Murat Tunaboylu. “This Series A financing enables us to scale our generative antibody design platform, accelerate our internal pipeline, and expand collaborations such as our work with the Cystic Fibrosis Foundation.”

Photo: Murat Tunaboylu, co-founder and CEO of Antiverse.